Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Other ORP type
Data sources: ZENODO
Zenodo
Claim

What is the efficacy of crizanlizumab in reducing the frequency and intensity of vaso-occlusive crises in patients with sickle cell disease?

descriptionPublicationkeyboard_double_arrow_right Other ORP type Under curationPublisher:Zenodo
Authors: Tripdatabase;

doi: 10.5281/zenodo.20553079

What is the efficacy of crizanlizumab in reducing the frequency and intensity of vaso-occlusive crises in patients with sickle cell disease?

Abstract

Crizanlizumab has been shown to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease based on both clinical trials and real-world data, though some trials have shown mixed results.

Powered by OpenAIRE graph
Found an issue? Give us feedback